We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Dulaglutide (GLP-1 receptor agonist)
An FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is a prescription drug, not a supplement, and is never auto-recommended.
Prescription medication — not a dietary supplement
Dulaglutide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Dulaglutide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2012–2026 with a typical study size of 607 participants.
Based on 143 studies · 15 meta-analyses · 107 RCTs · 607 total participants
Confidence
High confidenceBy outcome
Strong, consistent large-RCT evidence from the AWARD program plus the 9,901-patient REWIND cardiovascular-outcomes trial and confirmatory meta-analyses; capped below top tier because it is a prescription drug with notable risks, not a supplement.
114 randomised trials
94% were about Dulaglutide in an audit of 50 of them
Every randomised or controlled trial of Dulaglutide indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
24 trials ongoing or recruiting · 102 completed on ClinicalTrials.gov
58 of the completed trials have posted results
Registered trials show research momentum for Dulaglutide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Dulaglutide is a long-acting analogue of the gut incretin hormone GLP-1 (glucagon-like peptide-1), formatted as a fusion of two GLP-1 analogue molecules to an Fc fragment so it can be dosed once weekly by subcutaneous injection.
It is a prescription drug, NOT a dietary supplement: branded as Trulicity and approved by the FDA for type 2 diabetes, with an additional indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), brain (appetite suppression and satiety), and gut (slowed gastric emptying). The evidence base is genuinely strong.
The AWARD program — a series of phase-3 RCTs — established efficacy across the diabetes treatment ladder: dulaglutide beat placebo and exenatide (AWARD-1), was non-inferior to once-daily liraglutide on HbA1c (AWARD-6), was superior to insulin glargine on HbA1c with weight loss instead of weight gain (AWARD-2), worked as add-on to SGLT2 inhibitors (AWARD-10), and showed dose-related additional HbA1c lowering at the higher 3.0/4.5 mg doses (AWARD-11).
The landmark REWIND cardiovascular-outcomes trial randomized 9,901 patients with type 2 diabetes — most WITHOUT prior cardiovascular disease — and found a 12% relative reduction in the composite of cardiovascular death, non-fatal MI, or non-fatal stroke (HR 0.88, 95% CI 0.79-0.99) over a median 5.4 years, with exploratory benefits on renal outcomes.
A pooled meta-analysis of all seven GLP-1 cardiovascular-outcomes trials (including REWIND) confirmed a class-level 12% MACE reduction (HR 0.88) and a 17% reduction in a composite kidney outcome, with no increase in pancreatitis or pancreatic cancer.
The honest counterweight: in the US, FDA labeling for dulaglutide carries a boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma) and under that US label is contraindicated with a personal/family history of medullary thyroid carcinoma or MEN2; it carries risks of pancreatitis and gallbladder disease; gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common; its weight loss is real but modest (typically a few kilograms, less than semaglutide — head-to-head SUSTAIN 7 showed semaglutide lowered HbA1c and weight more); and FDA-equivalent warnings about compounded/grey-market GLP-1 products apply.
It should be used only under a clinician's care, for a genuine medical indication.
A long-acting GLP-1 analogue (fused to an Fc fragment for once-weekly dosing) that binds and activates the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract — the single upstream target driving all downstream effects.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering fasting and postprandial glucose and HbA1c with low intrinsic hypoglycemia risk.
Acts on central appetite-regulating circuits to increase satiety and reduce food intake — the driver of the modest weight loss (typically a few kilograms) seen across the AWARD trials.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the nausea seen during initiation.
How Dulaglutide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated — under the US label, which carries a US FDA boxed warning for thyroid C-cell tumors. In Germany or Austria, the current product information for the exact medicine applies.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Contraindicated — discontinue before a planned pregnancy under clinician guidance.
Not appropriate — this is a prescription diabetes drug with real risks, not a cosmetic shortcut. Use only for a clinician-confirmed indication.
Combining with insulin or sulfonylureas raises hypoglycemia risk; the clinician typically reduces those agents. Dulaglutide alone is low-hypoglycemia (glucose-dependent action).
Delayed gastric emptying can change the absorption of co-administered oral drugs; clinician monitoring advised, especially for narrow-therapeutic-index medicines.
Do not combine with another GLP-1 agonist (e.g. semaglutide, liraglutide, exenatide) or a GIP/GLP-1 agonist (tirzepatide) — additive risk with no added benefit.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Seek care for upper-right abdominal pain, fever, or jaundice
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
Tip: Asymptomatic enzyme elevations are recognized; clinician monitors and evaluates symptomatic cases
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment. Dose reduction of background insulin/sulfonylurea by the prescribing clinician.
Dulaglutide has an evidence score of 7/10 — strong evidence based on 143 indexed studies, including 2 meta-analyses. An FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is a prescription drug, not a supplement, and is never auto-recommended. Representative study: PMID 31422062.
Dosing for Dulaglutide: Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Dulaglutide — consistent daily use matters more than the time of day. Once-weekly subcutaneous injection on the same day each week, with or without food, at any time of day.
Dulaglutide should be used with caution — talk to a healthcare provider before taking it. Reported side effects include acute pancreatitis, gallbladder disease (cholelithiasis / cholecystitis), hypoglycemia (with insulin/sulfonylurea). How often they occur is not established for all of them. Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label); Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label); Prior serious hypersensitivity to dulaglutide or any GLP-1 receptor agonist.
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Orforglipron
Too few graded studiesAn ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity, also studied in type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026. An EMA list dated 5 October 2026 places orforglipron under evaluation. Honest appraisal: the phase-2 data are strong and the phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), the US label carries a boxed warning about thyroid C-cell tumours, and long-term outcomes are unsettled. It is NOT a dietary supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 143 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research